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Introduction {#bjs550264-sec-0005}
============

Despite advances in treatment, oesophageal cancer remains the sixth most common cause of cancer‐related mortality worldwide, with an increasing incidence in the West[1](#bjs550264-bib-0001){ref-type="ref"}, [2](#bjs550264-bib-0002){ref-type="ref"}. The mainstay of curative therapy for locoregional oesophageal cancer is oesophagectomy, although this procedure is possible only in selected patients. Even in this subset, resection is associated with significant morbidity and mortality[3](#bjs550264-bib-0003){ref-type="ref"}, [4](#bjs550264-bib-0004){ref-type="ref"}. Recent series[5](#bjs550264-bib-0005){ref-type="ref"}, [6](#bjs550264-bib-0006){ref-type="ref"}, [7](#bjs550264-bib-0007){ref-type="ref"}, [8](#bjs550264-bib-0008){ref-type="ref"}, [9](#bjs550264-bib-0009){ref-type="ref"}, [10](#bjs550264-bib-0010){ref-type="ref"} have reported complications in 30--70 per cent of patients. Serious complications, including anastomotic leak, conduit necrosis and pulmonary complications, lead to an increased length of hospital stay and return to theatre, and decreased overall survival[11](#bjs550264-bib-0011){ref-type="ref"}, [12](#bjs550264-bib-0012){ref-type="ref"}.

Recent evidence[3](#bjs550264-bib-0003){ref-type="ref"}, [6](#bjs550264-bib-0006){ref-type="ref"}, [13](#bjs550264-bib-0013){ref-type="ref"}, [14](#bjs550264-bib-0014){ref-type="ref"}, [15](#bjs550264-bib-0015){ref-type="ref"}, [16](#bjs550264-bib-0016){ref-type="ref"} also suggests that complications after oesophagectomy may decrease overall and disease‐specific survival in patients with complications that resolve initially. A recent systematic review[3](#bjs550264-bib-0003){ref-type="ref"} found that postoperative complications decreased survival following oesophagectomy. However, before publication of the consensus reporting guidelines on oesophageal complications[11](#bjs550264-bib-0011){ref-type="ref"}, a lack of standardization of complication reporting made understanding the relationship between complications and long‐term survival difficult.

This study aimed to identify preoperative and perioperative factors associated with the development of complications, and to examine the effect of complication grade on overall and recurrence‐free survival.

Methods {#bjs550264-sec-0006}
=======

All consecutive patients who had oesophagectomy for oesophageal cancer at a tertiary referral centre (Queen Elizabeth Hospital, Birmingham) between January 2006 and February 2017*,* identified from a prospectively developed database, were included in the study. Patients were followed up for a minimum of 28 months to June 2019. Patients with inoperable disease undergoing 'open and close' procedures, with no resection, were excluded. The data set included demographic, treatment and pathology details along with complications[17](#bjs550264-bib-0017){ref-type="ref"}, [18](#bjs550264-bib-0018){ref-type="ref"}, [19](#bjs550264-bib-0019){ref-type="ref"}, [20](#bjs550264-bib-0020){ref-type="ref"}, [21](#bjs550264-bib-0021){ref-type="ref"}. The study was approved by the Queen Elizabeth Hospital clinical audit department. Ethics committee approval was waived, given the nature of the study. Patients did not receive neoadjuvant chemotherapy when: they declined the option after discussion with a consultant oncologist; they had co‐morbidity for which the risks of chemotherapy were considered to outweigh the advantages (for instance patients with renal impairment or cardiovascular disease); or they had tumour staged before surgery as T2 disease or lower. All patients undergoing oesophagectomy with non‐benign findings on histological examination were included.

Operations {#bjs550264-sec-0007}
----------

Over the 11‐year period, oesophagectomies were performed by ten specialist upper gastrointestinal consultant surgeons, or trainees under supervision, and classified as open, minimally invasive or hybrid. The decision regarding surgical approach was at the discretion of the consultant surgeon. Completely minimally invasive procedures were introduced in 2008. Anastomotic techniques included hand‐sewn, circular stapled, OrVil™ (Covidien, Mansfield, MA, USA) and semimechanical anastomoses. Postoperative nutritional support was used routinely via feeding jejunostomy, unless, for technical reasons, nasojejunal feeding or total parenteral nutrition was needed. After surgery, all patients were managed initially in a critical care unit before transfer to standard ward care when considered fit. R1 resections were those in which the tumour was present microscopically within 1 mm of the circumferential, distal or proximal margins, as described by the Royal College of Pathologists[22](#bjs550264-bib-0022){ref-type="ref"}; R2 resections were those in which tumour could not be removed completely, leaving macroscopic residual tumour.

Complications {#bjs550264-sec-0008}
-------------

All postoperative complications were classified according to the standardized definitions proposed by the Esophageal Complications Consensus Group[11](#bjs550264-bib-0011){ref-type="ref"}. All complications were graded according to both the Comprehensive Complication Index (CCI) and the Clavien--Dindo classification.

In summary, the Clavien--Dindo system classifies complications as follows. Grade I includes any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic or radiological interventions. Acceptable therapeutic regimens are antiemetics, antipyretics, analgesics, diuretics, electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. Grade II includes any complication requiring pharmacological treatment, not allowed in grade I. Grade III includes any complication requiring surgical, endoscopic or radiological intervention. Grade IV includes single or multiple organ failure, requiring ICU management, and grade V denotes inpatient death.

The CCI produces a score between 1 and 100, allowing for multiple complications, and based on the ranking scale used in the Clavien--Dindo system[23](#bjs550264-bib-0023){ref-type="ref"}. Anastomotic leak, chyle leak, conduit necrosis and vocal cord palsy were also graded in severity from I to III, based on the grading proposed by the Esophageal Complications Consensus Group.

Survival data {#bjs550264-sec-0009}
-------------

Patient survival was calculated from the time of surgery, and censored at the final follow‐up. For analysis of recurrence‐free survival, patients with R2 resections were excluded. Although inpatient death is considered a complication in the Clavien--Dindo grading system (grade V), it was not meaningful to include these patients in the comparisons of long‐term survival by complication grade. As a result, all patients who died as inpatients, and those who died or were lost to follow‐up within 90 days of surgery, were excluded from survival analyses.

Statistical analysis {#bjs550264-sec-0010}
--------------------

Initially, the demographics of the cohort were summarized, using mean(s.d.) and median (i.q.r.) values as appropriate. Patients were then divided into groups based on the highest Clavien--Dindo complication grade: no complication, grades I*--*II and grades III--V. Comparisons between these groups were performed using Jonckheere--Terpstra tests for continuous variables and Kendall\'s τ for ordinal variables. For nominal variables, the complication grade was compared across categories using the Kruskal--Wallis test.

Postoperative patient survival was compared across complication grades using Kaplan--Meier curves, with univariable Cox regression models to produce hazard ratios (HRs). Multivariable Cox regression models were then produced, to account for the effects of potentially confounding factors, using a backwards stepwise approach to variable selection. All preoperative and intraoperative factors with at least 90 per cent completeness of data were considered initially for inclusion in the models. Before analysis, continuous variables were divided into categories based on the quartiles of the distribution, in order to improve model fit. Factors selected for inclusion by the stepwise procedure were then entered into a new model, to maximize the included sample size, by preventing exclusions owing to missing data for non‐significant factors. As a sensitivity analysis, factors with less than 90 per cent data completeness were then added to the final model, to test whether any of these were significant independent predictors of patient outcomes.

All analyses were performed using IBM SPSS® version 22 (IBM, Armonk, New York, USA), with *P* \< 0·050 deemed to be indicative of statistical significance throughout.

Results {#bjs550264-sec-0011}
=======

Data were available for a total of 430 patients undergoing surgery between 1 January 2006 and 28 February 2017. The mean(s.d.) age at surgery was 64·9(9·4) years, and the majority of patients were men (79·5 per cent). The majority of patients had preoperative chemotherapy (342 of 430, 79·5 per cent), with the remainder receiving no neoadjuvant therapy. Postoperative histological examination revealed that the majority of the 430 patients had either adenocarcinoma (337, 78·4 per cent) or squamous cell carcinoma (70, 16·3 per cent); the rest had either adenosquamous carcinoma (8, 1·9 per cent) or another malignant cancer (15, 3·5 per cent). Complete patient details including tumour and perioperative/postoperative factors are shown in *Tables* [1](#bjs550264-tbl-0001){ref-type="table"}, [2](#bjs550264-tbl-0002){ref-type="table"}, [3](#bjs550264-tbl-0003){ref-type="table"}.

###### 

Associations between complication grade and patient demographics and co‐morbidity

                                                                                               Highest Clavien--Dindo grade                                          
  ------------------------------------------------------------------------ ----- ------------ ------------------------------ ------------------- ------------------- -----------------------------------------------
  **Age at operation (years)** [\*](#bjs550264-note-0003){ref-type="fn"}    430   64·9(9·4)             63·7(10·3)                65·6(8·5)           65·3(9·2)       0·162[§](#bjs550264-note-0006){ref-type="fn"}
  **Male sex**                                                              430   342 (79·5)        109 of 138 (79·0)         120 of 144 (83·3)   113 of 148 (76·4)                       0·566
  **BMI (kg/m** ^**2**^ **)** [\*](#bjs550264-note-0003){ref-type="fn"}     409   26·4(4·9)             27·1(5·4)                 26·2(4·9)           25·9(4·4)       0·139[§](#bjs550264-note-0006){ref-type="fn"}
  **ASA grade**                                                             390                         *n* = 117                 *n* = 138           *n* = 135                           0·032
  1                                                                               79 (20·3)             25 (21·4)                 31 (22·5)           23 (17·0)      
  2                                                                               207 (53·1)            67 (57·3)                 75 (54·3)           65 (48·1)      
  3                                                                               96 (24·6)             22 (18·8)                 31 (22·5)           43 (31·9)      
  4                                                                                8 (2·1)               3 (2·6)                   1 (0·7)             4 (3·0)       
  **ECOG performance score**                                                303                          *n* = 93                 *n* = 110           *n* = 100                           0·041
  0                                                                               134 (44·2)             48 (52)                  51 (46·4)           35 (35·0)      
  1                                                                               136 (44·9)             33 (35)                  52 (47·3)           51 (51·0)      
  2                                                                               33 (10·9)              12 (13)                   7 (6·4)            14 (14·0)      
  **Co‐morbidity**                                                                                      *n* = 125                 *n* = 138           *n* = 140      
  Ischaemic heart disease                                                   403   53 (13·2)             13 (10·4)                 18 (13·0)           22 (15·7)                           0·198
  Renal impairment                                                          403    4 (1·0)               2 (1·6)                   1 (0·7)             1 (0·7)                            0·512
  Diabetic                                                                  403   48 (11·9)              10 (8·0)                 18 (13·0)           20 (14·3)                           0·109
  COPD                                                                      403    31 (7·7)              7 (5·6)                  10 (7·2)            14 (10·0)                           0·178
  Previous cancer                                                           403    19 (4·7)              5 (4·0)                   4 (2·9)            10 (7·1)                            0·242
  Significant smoking history                                               403   60 (14·9)             14 (11·2)                 25 (18·1)           21 (15·0)                           0·399
  Alcohol misuse/heavy drinker                                              403    9 (2·2)               1 (0·8)                   4 (2·9)             4 (2·9)                            0·226

Values in parentheses are percentages unless indicated otherwise;

values are mean(s.d.).

Number of patients with data available for the stated factor. ECOG, Eastern Cooperative Oncology Group; COPD, chronic obstructive pulmonary disease.

Kendall\'s τ, except

Jonckheere--Terpstra test.

###### 

Associations between complication grade and pathology

                                                                                              Highest Clavien--Dindo grade                                        
  ---------------------------------------------------------------------- ----- ------------- ------------------------------ ------------------ ------------------ -----------------------------------------------
  **Type of tumour**                                                      430                          *n* = 138                *n* = 144          *n* = 148       0·490[§](#bjs550264-note-0011){ref-type="fn"}
  Adenocarcinoma                                                                337 (78·4)             110 (79·7)               119 (82·6)         108 (73·0)     
  Squamous                                                                       70 (16·3)             21 (15·2)                17 (11·8)          32 (21·6)      
  Adenosquamous                                                                   8 (1·9)               2 (1·4)                  4 (2·8)            2 (1·4)       
  Other                                                                          15 (3·5)               5 (3·6)                  4 (2·8)            6 (4·1)       
  **Tumour location**                                                     392                          *n* = 118                *n* = 134          *n* = 140       0·208[§](#bjs550264-note-0011){ref-type="fn"}
  GOJ                                                                           236 (60·2)             81 (68·6)                74 (55·2)          81 (57·9)      
  Distal                                                                        132 (33·7)             30 (25·4)                51 (38·1)          51 (36·4)      
  Middle                                                                         24 (6·1)               7 (5·9)                  9 (6·7)            8 (5·7)       
  **pT category**                                                         427                          *n* = 135                *n* = 144          *n* = 148                            0·071
  pT0                                                                            19 (4·4)               5 (3·7)                  8 (5·6)            6 (4·1)       
  pT1                                                                            52 (12·2)              13 (9·6)                18 (12·5)          21 (14·2)      
  pT2                                                                            54 (12·6)             15 (11·1)                 14 (9·7)          25 (16·9)      
  pT3                                                                           277 (64·9)             93 (68·9)                96 (66·7)          88 (59·5)      
  pT4                                                                            25 (5·9)               9 (6·7)                  8 (5·6)            8 (5·4)       
  **pN category**                                                         429                          *n* = 137                *n* = 144          *n* = 148                            0·882
  pN0                                                                           164 (38·2)             57 (41·6)                46 (31·9)          61 (41·2)      
  pN1                                                                           186 (43·4)             57 (41·6)                65 (45·1)          64 (43·2)      
  pN2                                                                            46 (10·7)              13 (9·5)                20 (13·9)           13 (8·8)      
  pN3                                                                            33 (7·7)               10 (7·3)                 13 (9·0)           10 (6·8)      
  **pM1 status**                                                          430     9 (2·1)            3 of 138 (2·2)           2 of 144 (1·4)     4 of 148 (2·7)                         0·757
  **Overall stage**                                                       425                          *n* = 134                *n* = 144          *n* = 147                            0·428
  0                                                                              15 (3·5)               4 (3·0)                  5 (3·5)            6 (4·1)       
  1                                                                              74 (17·4)             18 (13·4)                24 (16·7)          32 (21·8)      
  2                                                                              95 (22·4)             39 (29·1)                25 (17·4)          31 (21·1)      
  3                                                                             232 (54·6)             70 (52·2)                88 (61·1)          74 (50·3)      
  4                                                                               9 (2·1)               3 (2·2)                  2 (1·4)            4 (2·7)       
  **Perineural invasion**                                                 331   105 (31·7)          38 of 114 (33·3)         40 of 115 (34·8)   27 of 102 (26·5)                        0·291
  **Tumour dimensions (mm)** [\*](#bjs550264-note-0008){ref-type="fn"}                                                                                            
  Length                                                                  394   35 (25--45)           35 (25--45)              34 (25--45)        35 (25--48)      0·766[¶](#bjs550264-note-0012){ref-type="fn"}
  Width                                                                   382   26 (20--40)           25 (18--40)              25 (20--35)        30 (20--37)      0·774[¶](#bjs550264-note-0012){ref-type="fn"}
  Depth                                                                   310   12 (8--15)             12 (8--16)               11 (7--15)         12 (8--16)      0·634[¶](#bjs550264-note-0012){ref-type="fn"}
  Maximum dimension                                                       402   35 (25--50)           36 (25--50)              35 (25--50)        35 (25--50)      0·753[¶](#bjs550264-note-0012){ref-type="fn"}

Values in parentheses are percentages unless indicated otherwise;

values are median (i.q.r.).

Number of patients with data available for the stated factor. GOJ, gastro‐oesophageal junction.

Kendall\'s τ, except

Kruskal--Wallis test and

Jonckheere--Terpstra test.

###### 

Associations between complication grade and intraoperative and postoperative factors

                                                                                                                                                    Highest Clavien--Dindo grade                                          
  ---------------------------------------------------------------------------------------------------------------------------- ----- ------------- ------------------------------ ------------------- ------------------- ----------------------------------------------------
  **Type of operation**                                                                                                         430                          *n* = 138                 *n* = 144           *n* = 148         0·436[\*\*](#bjs550264-note-0019){ref-type="fn"}
  Hybrid                                                                                                                              223 (51·9)             71 (51·4)                 70 (48·6)           82 (55·4)      
  MIO                                                                                                                                 101 (23·5)             26 (18·8)                 43 (29·9)           32 (21·6)      
  Open                                                                                                                                106 (24·7)             41 (29·7)                 31 (21·5)           34 (23·0)      
  **Total no. of LNs** [\*](#bjs550264-note-0014){ref-type="fn"}                                                                429   30·3(11·5)             31·4(11·6)               29·5(11·1)          30·0(11·8)         0·239[††](#bjs550264-note-0020){ref-type="fn"}
  **No. of LNs involved** [†](#bjs550264-note-0015){ref-type="fn"}                                                              429    1 (0--4)               1 (0--3)                 2 (0--4)            1 (0--4)          0·778[††](#bjs550264-note-0020){ref-type="fn"}
  **% of LNs involved** [†](#bjs550264-note-0015){ref-type="fn"}                                                                429    4 (0--13)             4 (0--10)                 7 (0--16)           4 (0--13)         0·783[††](#bjs550264-note-0020){ref-type="fn"}
  **Margins involved**                                                                                                                                                                                                    
  Proximal                                                                                                                      428    11 (2·6)            5 of 138 (3·6)           4 of 143 (2·8)      2 of 147 (1·4)                           0·211
  Distal                                                                                                                        428     5 (1·2)             0 of 138 (0)            2 of 143 (1·4)      3 of 147 (2·0)                           0·089
  Circumferential                                                                                                               420   140 (33·3)          40 of 132 (30·3)         54 of 141 (38·3)    46 of 147 (31·3)                          0·916
  **R status**                                                                                                                  423                          *n* = 133                 *n* = 143           *n* = 147                             0·682
  R0                                                                                                                                  257 (60·8)             82 (61·7)                 81 (56·6)           94 (63·9)      
  R1                                                                                                                                  152 (35·9)             48 (36·1)                 55 (38·5)           49 (33·3)      
  R2                                                                                                                                   14 (3·3)               3 (2·3)                   7 (4·9)             4 (2·7)       
  **Total intraoperative/postoperative blood loss (units)**                                                                     430                          *n* = 138                 *n* = 144           *n* = 148                            \< 0·001
  0                                                                                                                                   332 (77·2)             116 (84·1)               122 (84·7)           94 (63·5)      
  1--2                                                                                                                                 78 (18·1)             19 (13·8)                 15 (10·4)           44 (29·7)      
  ≥ 3                                                                                                                                  20 (4·7)               3 (2·2)                   7 (4·9)            10 (6·8)       
  **CRP (mg/l) on day 4** [\*](#bjs550264-note-0014){ref-type="fn"}, [§](#bjs550264-note-0017){ref-type="fn"}                                                                                                             
  Actual                                                                                                                        285   217·3(94·8)           196·5(84·4)               200·5(87·6)        247·1(101·0)      \< 0·001[††](#bjs550264-note-0020){ref-type="fn"}
  LMCF                                                                                                                          419   207·5(93·5)           188·8(81·5)               196·9(87·5)        236·9(103·6)      \< 0·001[††](#bjs550264-note-0020){ref-type="fn"}
  **Albumin (g/l) on day 4** [\*](#bjs550264-note-0014){ref-type="fn"}, [§](#bjs550264-note-0017){ref-type="fn"}                                                                                                          
  Actual                                                                                                                        319    26·6(4·5)             27·7(3·7)                 27·6(4·6)           24·6(4·3)       \< 0·001[††](#bjs550264-note-0020){ref-type="fn"}
  LMCF                                                                                                                          423    26·8(4·4)             27·9(3·8)                 27·6(4·4)           24·9(4·5)       \< 0·001[††](#bjs550264-note-0020){ref-type="fn"}
  **WCC (× 10** ^**9**^ **/l) on day 4** [\*](#bjs550264-note-0014){ref-type="fn"}, [§](#bjs550264-note-0017){ref-type="fn"}                                                                                              
  Actual                                                                                                                        351    9·5(3·5)               9·0(3·0)                 9·3(2·9)            10·1(4·2)         0·050[††](#bjs550264-note-0020){ref-type="fn"}
  LMCF                                                                                                                          424    9·8(3·7)               9·6(3·7)                 9·5(3·2)            10·3(4·2)         0·123[††](#bjs550264-note-0020){ref-type="fn"}
  **Neoadjuvant chemotherapy**                                                                                                  430   342 (79·5)         112 of 138 (81·2)         113 of 144 (78·5)   117 of 148 (79·1)                         0·665
  **Return to theatre**                                                                                                         430    90 (20·9)           2 of 138 (1·4)           1 of 144 (0·7)     87 of 148 (58·8)                         \< 0·001
  **Return to ICU**                                                                                                             426    86 (20·2)            0 of 137 (0)            8 of 143 (5·6)     78 of 146 (53·4)                         \< 0·001
  **Total length of hospital stay (days)** [†](#bjs550264-note-0015){ref-type="fn"}                                             430   16 (11--25)            12 (9--15)               16 (11--20)         27 (17--43)      \< 0·001[††](#bjs550264-note-0020){ref-type="fn"}
  **Total length of ICU stay (days)** [†](#bjs550264-note-0015){ref-type="fn"}                                                  430    5 (2--10)              3 (2--4)                 4 (2--7)           11 (5--19)       \< 0·001[††](#bjs550264-note-0020){ref-type="fn"}

Values in parentheses are percentages unless indicated otherwise;

values are mean(s.d.) and

median (i.q.r.).

Number of patients with data available for the stated factor.

'Actual' gives measurements recorded on day 4, whereas last measure carried forward (LCMF) fills in missing data using the most recent value obtained before day 4, where possible. MIO, minimally invasive operation; LN, lymph node; CRP, C‐reactive protein; WCC, white cell count.

Kendall\'s τ, except

Kruskal--Wallis test and

Jonckheere--Terpstra test.

Complications {#bjs550264-sec-0012}
-------------

A total of 292 patients (67·9 per cent) developed postoperative complications, the most common being infection (49·8 per cent), pulmonary (46·5 per cent) and gastrointestinal (24·9 per cent) related (*Table* [4](#bjs550264-tbl-0004){ref-type="table"}). For 144 patients (33·5 per cent), the highest recorded Clavien--Dindo grade was I or II, and 128 patients (29·8 per cent) had grade III or IV as the highest recorded grade. The remaining 20 patients died in hospital (Clavien--Dindo grade V). The CCI score was available for only 383 patients (median 21 (i.q.r. 0--40)). The CCI score and Clavien--Dindo grade were highly correlated (*r* ~[s]{.smallcaps}~ = 0·91, *P* \< 0·001) (*Fig*. [*1*](#bjs550264-fig-0001){ref-type="fig"}), so only the Clavien--Dindo system was used in subsequent analyses.

###### 

Postoperative complications

                                                            Total *n* [‡](#bjs550264-note-0023){ref-type="fn"}   No. of patients[\*](#bjs550264-note-0021){ref-type="fn"}
  -------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------
  **Highest Clavien--Dindo grade**                                                 430                          
  No complications                                                                                                                      138 (32·1)
  I                                                                                                                                      21 (4·9)
  II                                                                                                                                    123 (28·6)
  III                                                                                                                                   67 (15·6)
  IV                                                                                                                                    61 (14·2)
  V (death)                                                                                                                              20 (4·7)
  **CCI score** [†](#bjs550264-note-0022){ref-type="fn"}                           383                                                  21 (0--40)
  **Type of complication**                                                         430                          
  None                                                                                                                                  138 (32·1)
  Medical only                                                                                                                          47 (10·9)
  Surgical only                                                                                                                         55 (12·8)
  Both medical and surgical                                                                                                             190 (44·2)
  **Infective complication**                                                       430                                                  214 (49·8)
  **Pulmonary complication**                                                       430                                                  200 (46·5)
  **Gastrointestinal complication**                                                430                                                  107 (24·9)
  **Cardiac complication**                                                         430                                                  91 (21·2)
  **Neurological/psychiatric complication**                                        430                                                   21 (4·9)
  **Wound/diaphragm complication**                                                 430                                                   18 (4·2)
  **Urological complication**                                                      430                                                   14 (3·3)
  **Thromboembolic complication**                                                  430                                                   6 (1·4)
  **Anastomotic leak grade**                                                       430                          
  No leak                                                                                                                               363 (84·4)
  I                                                                                                                                      14 (3·3)
  II                                                                                                                                     18 (4·2)
  III                                                                                                                                    35 (8·1)
  **Conduit necrosis grade**                                                       430                          
  No necrosis                                                                                                                           416 (96·7)
  I                                                                                                                                      1 (0·2)
  II                                                                                                                                     5 (1·2)
  III                                                                                                                                    8 (1·9)
  **Chyle leak grade**                                                             430                          
  No leak                                                                                                                               399 (92·8)
  I                                                                                                                                      19 (4·4)
  II                                                                                                                                     3 (0·7)
  III                                                                                                                                    9 (2·1)
  **Vocal cord palsy grade**                                                       430                          
  No palsy                                                                                                                              417 (97·0)
  I                                                                                                                                      8 (1·9)
  II                                                                                                                                     4 (0·9)
  III                                                                                                                                    1 (0·2)

With percentages in parentheses unless indicated otherwise;

values are median (i.q.r.).

Number of patients with data available for the stated factor. CCI, Comprehensive Complication Index.

![Box‐and‐whisker plot of the association between Clavien--Dindo grade and Comprehensive Complication Index score in patients with complications The plot is based on 242 patients, after excluding 138 with no complications, 20 who died after surgery (Clavien--Dindo grade V/Comprehensive Complication Index (CCI) score 100) and 30 with no CCI score recorded. Median values, interquartile ranges and ranges (excluding outliers) are denoted by horizontal bars, boxes and error bars respectively (*r* ~[s]{.smallcaps}~ = 0·91, *P* \< 0·001).](BJS5-4-405-g001){#bjs550264-fig-0001}

Factors associated with complication grade {#bjs550264-sec-0013}
------------------------------------------

Patients who developed complications were generally similar to those without complications with regard to demographic (*Table* [1](#bjs550264-tbl-0001){ref-type="table"}) and tumour‐related (*Table* [2](#bjs550264-tbl-0002){ref-type="table"}) factors. The only significant differences were in the ASA grade (*P* = 0·032) and ECOG score (*P* = 0·041), both of which increased with complication grade. Of the postoperative factors considered (*Table* [3](#bjs550264-tbl-0003){ref-type="table"}), patients with higher‐grade complications required significantly more units of blood, and also had significantly higher C‐reactive protein (CRP) and lower albumin levels on postoperative day 4 (all *P* \< 0·001). Patients with Clavien--Dindo grade III--V complications were significantly more likely than those with either no or minor complications to return to both theatre (87 of 148 (58·8 per cent) *versus* 3 of 282 (1·1 per cent) respectively; *P* \< 0·001) and ICU (78 of 146 (53·4 per cent) *versus* 8 of 280 (2·9 per cent); *P* \< 0·001). Consequently, the lengths of ITU and total hospital stay were significantly longer for patients with Clavien--Dindo grade III--V complications (both *P* \< 0·001).

Survival by complication grade {#bjs550264-sec-0014}
------------------------------

After exclusion of the 20 patients who died in hospital, a further 14 patients who were lost to follow‐up less than 90 days after surgery were also excluded. The remaining 396 patients had a median follow‐up of 23·6 (i.q.r. 13·5--50·7) months, during which there were 258 deaths, giving Kaplan--Meier‐estimated overall survival rates of 81·4, 44·5 and 33·1 at 1, 3 and 5 years respectively.

Patient survival was found to differ significantly by Clavien--Dindo grade (*P* \< 0·001) (*Table* [5](#bjs550264-tbl-0005){ref-type="table"} and *Fig*. [*2*](#bjs550264-fig-0002){ref-type="fig"}). Patients with grade I complications had similar overall survival to those with no complications (median 44 *versus* 51 months respectively) (HR 1·28, *P* = 0·419). However, higher‐grade complications were associated with significantly shorter survival: median survival 22, 27 and 20 months for Clavien--Dindo grades II, III and IV respectively. Analysis of recurrence‐free survival gave similar results.

###### 

Survival outcomes by Clavien--Dindo grade

                                      Overall survival   Recurrence‐free survival[†](#bjs550264-note-0025){ref-type="fn"}                                                                  
  ---------------------------------- ------------------ ------------------------------------------------------------------ ------------------- ---------- ----- ------ ------------------- ----------
  **Highest Clavien--Dindo grade**                                                                                                              \< 0·001                                    \< 0·001
  No complications                          133                                        51·0                                 1·00 (reference)               126   38·1   1·00 (reference)   
  I                                          19                                        44·1                                 1·28 (0·71, 2·31)     0·419    18    48·3   1·42 (0·79, 2·59)     0·245
  II                                        118                                        21·6                                 2·01 (1·46, 2·75)   \< 0·001   113   17·7   1·97 (1·43, 2·73)   \< 0·001
  III                                        67                                        26·7                                 1·40 (0·96, 2·04)     0·081    64    20·2   1·50 (1·03, 2·20)     0·036
  IV                                         59                                        19·9                                 1·97 (1·34, 2·90)   \< 0·001   57    16·5   1·95 (1·32, 2·88)   \< 0·001

Values in parentheses are 95 per cent confidence intervals. Patients who died or were lost to follow‐up within 90 days were excluded;

additionally excludes 18 patients with R2 or unknown resection status.

Kaplan--Meier estimates;

univariable Cox regression models.

![**Kaplan--Meier analysis of postoperative survival by highest Clavien--Dindo grade**\
**a** Overall and **b** recurrence‐free survival. Patients who died or were lost to follow‐up within 90 days (dotted line) were excluded. The plot of recurrence‐free survival additionally excludes 18 patients with R2 or unknown resection status.](BJS5-4-405-g002){#bjs550264-fig-0002}

Multivariable survival analysis included all of the factors in *Tables* [1](#bjs550264-tbl-0001){ref-type="table"}, [2](#bjs550264-tbl-0002){ref-type="table"}, [3](#bjs550264-tbl-0003){ref-type="table"}, alongside the Clavien--Dindo complication grade, except for total number of units of blood, return to theatre/ICU and lengths of hospital/ITU stay, as these were consequences of complications. Overall stage and number of lymph nodes involved were also excluded, as these were highly correlated with TNM staging and proportion of lymph nodes involved respectively. Finally, the ECOG score, tumour depth, length and width, and the presence of perineural invasion were initially excluded, as the amount of missing data exceeded 10 per cent.

For patient survival, the resulting model (*Table* [6](#bjs550264-tbl-0006){ref-type="table"}) found increasing proportions of lymph nodes involved, unsuspected M1 disease on postoperative histology and low albumin levels on postoperative day 4 to be the strongest predictors of poor prognosis (all *P* \< 0·001). After accounting for these and the other factors in the model, the association between Clavien--Dindo complication grade and overall survival remained significant (*P* = 0·029). The results were similar to those observed in the univariable analysis, with Clavien--Dindo grade I complications not found to influence survival significantly (HR 0·97, *P* = 0·915), but grade II (HR 1·64, *P* = 0·007) and grade IV (HR 1·74, *P* = 0·013) being significant independent predictors of poorer overall survival. However, overall survival after Clavien--Dindo grade III complications was not significantly different to that after no complications (HR 1·24, *P* = 0·336). Analysis of recurrence‐free survival returned similar results. As a sensitivity analysis, the factors excluded owing to excessive missing data were then added to the final models; none was found to be a significant independent predictor of either overall or recurrence‐free survival.

###### 

Multivariable analysis of survival outcomes

                                                                           Overall survival    Recurrence‐free survival                      
  ---------------------------------------------------------------------- -------------------- -------------------------- ------------------- ----------
  **Highest Clavien--Dindo grade**                                                                      0·029                                  0·041
  No complications                                                         1·00 (reference)                               1·00 (reference)   
  I                                                                       0·97 (0·51, 1·83)             0·915             1·37 (0·72, 2·62)    0·341
  II                                                                      1·64 (1·14, 2·35)             0·007             1·63 (1·13, 2·35)    0·009
  III                                                                     1·24 (0·80, 1·93)             0·336             1·22 (0·78, 1·90)    0·376
  IV                                                                      1·74 (1·13, 2·70)             0·013             1·82 (1·17, 2·82)    0·007
  **ASA grade**                                                                                         0·035                                  0·030
  I                                                                        1·00 (reference)                               1·00 (reference)   
  II                                                                      0·64 (0·45, 0·90)             0·011             0·64 (0·45, 0·91)    0·013
  III                                                                     0·91 (0·62, 1·35)             0·655             0·88 (0·59, 1·30)    0·526
  IV                                                                      0·56 (0·21, 1·47)             0·241             0·42 (0·16, 1·11)    0·080
  **pM1 status**                                                          5·34 (2·36, 12·05)           \< 0·001           2·97 (1·13, 7·80)    0·027
  **% of lymph nodes involved**                                                                        \< 0·001                               \< 0·001
  0                                                                        1·00 (reference)                               1·00 (reference)   
  1--5                                                                    1·54 (0·97, 2·45)             0·065             1·68 (1·05, 2·69)    0·030
  6--15                                                                   2·98 (2·04, 4·35)            \< 0·001           2·90 (1·98, 4·24)   \< 0·001
  \> 15                                                                   4·93 (3·33, 7·30)            \< 0·001           5·18 (3·44, 7·79)   \< 0·001
  **R1 status**                                                                  n.s.                                     1·33 (0·99, 1·79)    0·057
  **Distal margin involved**                                              0·27 (0·08, 0·88)             0·029                   n.s.         
  **Albumin (g/l) on day 4** [\*](#bjs550264-note-0029){ref-type="fn"}                                 \< 0·001                                0·015
  \< 24                                                                    1·00 (reference)                               1·00 (reference)   
  24--26                                                                  0·60 (0·40, 0·91)             0·015             0·75 (0·50, 1·13)    0·171
  27--29                                                                  0·50 (0·34, 0·75)            \< 0·001           0·61 (0·41, 0·90)    0·012
  ≥ 30                                                                    0·45 (0·30, 0·67)            \< 0·001           0·54 (0·37, 0·81)    0·003

Values in parentheses are 95 per cent confidence intervals. Cox regression models were used with a backwards stepwise approach to variable selection; all factors from *Tables* [1](#bjs550264-tbl-0001){ref-type="table"}, [2](#bjs550264-tbl-0002){ref-type="table"}, [3](#bjs550264-tbl-0003){ref-type="table"} with at least 90 per cent completeness of data were considered for inclusion in the models, with the exception of total units of blood, return to theatre/ICU and length of hospital/ICU stay. The backwards stepwise approach was then repeated for the factors selected by the initial model, to maximize the included sample size. The final models were based on 339 patients (218 events) for overall survival and 331 patients (214 events) for recurrence‐free survival. The latter model excluded patients with R2 resection status.

A last measure carried forwards approach was used to fill in missing data using the most recent measurement obtained before day 4, where possible. n.s., Not selected for inclusion in the final model by the stepwise procedure.

Discussion {#bjs550264-sec-0015}
==========

Clavien--Dindo grade II and IV complications were independently associated with significantly shorter overall and recurrence‐free postoperative survival in patients undergoing oesophagectomy for oesophageal cancer.

There are several possible reasons for the association between complications and poorer prognosis. Complications may lead to increased inflammation, affecting the immune system of patients after surgery and leading to increased production of proinflammatory cytokines such as interleukin (IL) 6 and IL‐8[24](#bjs550264-bib-0024){ref-type="ref"}. This has been hypothesized to decrease the ability of the immune system to repress tumour recurrence. Previous reports[25](#bjs550264-bib-0025){ref-type="ref"}, [26](#bjs550264-bib-0026){ref-type="ref"} have similarly implicated a variety of inflammatory mediators in cancer recurrence and progression. Inflammatory pathways acting within the tumour microenvironment are also known to contribute to tumour growth, and to promote both survival and the growth of micrometastases, locally and at distant sites[27](#bjs550264-bib-0027){ref-type="ref"}. The finding that there was a correlation between the Clavien--Dindo grade and both CRP and albumin levels on postoperative day 4 could be interpreted as supporting evidence for this hypothesis. Preoperative albumin concentration is a well known prognostic marker; however, fewer studies have assessed the prognostic value of postoperative albumin[18](#bjs550264-bib-0018){ref-type="ref"}. Although a decrease in albumin after surgery probably reflects the systemic inflammatory response to surgery and was associated with higher‐grade complications, decreased albumin levels have been shown to be associated with other adverse outcomes[28](#bjs550264-bib-0028){ref-type="ref"}, [29](#bjs550264-bib-0029){ref-type="ref"}, [30](#bjs550264-bib-0030){ref-type="ref"} and were independently predictive of survival in multivariable analysis in the present study.

This study included a large cohort of patients with oesophageal cancer, with almost complete follow‐up, and loss to follow‐up was accounted for in the modelling. The analysis of individual complication grades builds on the results of a recent systematic review[3](#bjs550264-bib-0003){ref-type="ref"}, allowing a more in‐depth picture of how complications affect overall survival and disease recurrence. Similar rates of complications and anastomotic leak have been reported in other recent Western cohorts[31](#bjs550264-bib-0031){ref-type="ref"}, [32](#bjs550264-bib-0032){ref-type="ref"}, [33](#bjs550264-bib-0033){ref-type="ref"}, [34](#bjs550264-bib-0034){ref-type="ref"}. It is worth noting that the present series included learning curves for minimally invasive oesophagectomy[35](#bjs550264-bib-0035){ref-type="ref"}, and a possible increase in leak rate as a result of the vascular endothelial growth factor inhibitors used in patients who took part in the ST03 trial[36](#bjs550264-bib-0036){ref-type="ref"}.

Limitations of the study include the length of the study period, which included the introduction of minimally invasive oesophagectomy with a number of different techniques. Neoadjuvant therapies changed over the study period, with initially the MAGIC[37](#bjs550264-bib-0037){ref-type="ref"} and then the OE02[38](#bjs550264-bib-0038){ref-type="ref"}, OE05[39](#bjs550264-bib-0039){ref-type="ref"} and ST03[36](#bjs550264-bib-0036){ref-type="ref"} trials ushering in an era of increasingly potent perioperative chemotherapy.

This study specifically analysed the impact of individual Clavien--Dindo grades on survival. Other studies generally combine grade III and IV complications, owing to sample size, and many have not analysed grade I or II complications at all[3](#bjs550264-bib-0003){ref-type="ref"}, [6](#bjs550264-bib-0006){ref-type="ref"}, [7](#bjs550264-bib-0007){ref-type="ref"}, [8](#bjs550264-bib-0008){ref-type="ref"}, [9](#bjs550264-bib-0009){ref-type="ref"}, [40](#bjs550264-bib-0040){ref-type="ref"}. In the present study, Clavien--Dindo grade II and IV complications were independently associated with decreased postoperative overall and recurrence‐free survival. However, although grade III complications were significantly associated with overall survival in univariable analysis, there was no significant association in multivariable analysis. This may be due to the relatively small number of patients with grade III complications and therefore an insufficient sample size for multivariable significance. An alternative explanation is that the early and aggressive treatment of complications with radiological, endoscopic or surgical methods could lead to a shorter period of physiological stress for patients, and thereby affect oncological outcomes. 'Failure to rescue' is a well known phenomenon[41](#bjs550264-bib-0041){ref-type="ref"}, [42](#bjs550264-bib-0042){ref-type="ref"}, impacting on short‐term survival after oesophagectomy, and possibly explaining differences in mortality between high‐ and low‐volume centres. Failure to identify complications early and treat patients may also contribute to a long‐term impact of complications on patient survival[41](#bjs550264-bib-0041){ref-type="ref"}, [42](#bjs550264-bib-0042){ref-type="ref"}, [43](#bjs550264-bib-0043){ref-type="ref"}.

As complications were independently predictive of survival, regardless of tumour stage or grade, it follows that reducing the likelihood of complications may improve survival. Recent studies have focused on prehabilitation[44](#bjs550264-bib-0044){ref-type="ref"}, enhanced recovery after surgery[45](#bjs550264-bib-0045){ref-type="ref"}, intensive postoperative physiotherapy and incentive spirometry[46](#bjs550264-bib-0046){ref-type="ref"}, with mixed findings. Additionally, minimally invasive and hybrid oesophagectomy techniques appear to reduce pulmonary complications[47](#bjs550264-bib-0047){ref-type="ref"}, [48](#bjs550264-bib-0048){ref-type="ref"}. In the present study, no association existed between operative technique and complications, although the impact of learning curves merits consideration[35](#bjs550264-bib-0035){ref-type="ref"}. Techniques that might decrease anastomotic leak rates, such as omental wrapping[49](#bjs550264-bib-0049){ref-type="ref"} and indocyanine green[50](#bjs550264-bib-0050){ref-type="ref"} assessment, may impact on survival in the future.
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